Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,881,341
  • Shares Outstanding, K 308,996
  • Annual Sales, $ 967,780 K
  • Annual Income, $ 321,010 K
  • 60-Month Beta 1.33
  • Price/Sales 7.21
  • Price/Cash Flow 20.82
  • Price/Book 3.80
Trade EXEL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.05
  • Number of Estimates 4
  • High Estimate 0.08
  • Low Estimate 0.00
  • Prior Year 0.31
  • Growth Rate Est. (year over year) -83.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.22 +0.23%
on 10/20/20
26.50 -15.96%
on 09/21/20
-4.53 (-16.90%)
since 09/18/20
3-Month
19.84 +12.25%
on 09/04/20
27.35 -18.57%
on 09/16/20
-3.33 (-13.01%)
since 07/20/20
52-Week
13.67 +62.91%
on 03/17/20
27.80 -19.89%
on 05/12/20
+5.85 (+35.63%)
since 10/18/19

Most Recent Stories

More News
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC

Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.

PFE : 37.49 (-0.82%)
MRK : 78.27 (-0.51%)
EXEL : 22.27 (-1.33%)
BMY : 60.64 (-0.21%)
U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO(R) (nivolumab) in Combination with CABOMETYX(R) (cabozantinib) in Advanced Renal Cell Carcinoma

--Applications based on pivotal Phase 3 CheckMate -9ER trial, which showed OPDIVO in combination with CABOMETYX improved overall survival, doubled median progression-free survival and objective response...

BMY : 60.64 (-0.21%)
EXEL : 22.27 (-1.33%)
Roche's (RHHBY) 9M20 Sales Affected by COVID-19 Outbreak

Roche's (RHHBY) performance in the first nine months gets negatively impacted by coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

REGN : 576.63 (-1.12%)
RHHBY : 42.1100 (-0.59%)
EXEL : 22.27 (-1.33%)
NVS : 85.69 (-0.12%)
Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor

Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent anti-tumor activity in a large panel of cancer cell...

EXEL : 22.27 (-1.33%)
Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor

--- Clinical pharmacokinetic (PK) data suggest a significantly shorter half-life than cabozantinib -

EXEL : 22.27 (-1.33%)
Researchers Look for New Ways to Boost Diagnostic Capabilities

, /PRNewswire/ -- The global cancer diagnostics market is of the more innovative segments of the global diagnostics industry today. Cancer is one of the leading causes of death across the world, and its...

ANPC : 3.42 (-1.72%)
BLUE : 55.00 (+0.82%)
GSK : 36.04 (-0.39%)
EXEL : 22.27 (-1.33%)
EXAS : 103.02 (-3.85%)
4 Growth Stocks set to SOAR in 2021

Horizon Therapeutics (HZNP), Exelixis (EXEL), Freshpet (FRPT), and Halozyme Therapeutics (HALO) are well-positioned to keep gaining in 2021 based on their earnings and revenue growth potential in hot sectors....

HZNP : 74.31 (-5.29%)
EXEL : 22.27 (-1.33%)
FRPT : 119.54 (-3.66%)
HALO : 30.22 (+2.58%)
Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab

--- Data presented during the European Society for Medical Oncology Virtual Congress 2020 -

EXEL : 22.27 (-1.33%)
Roche's Tecentriq + Avastin Gets Positive CHMP Opinion for HCC

Roche's (RHHBY) combination of immuno-oncology drug, Tecentriq, and Avastin gets positive CHMP opinion for the treatment of advanced or unresectable HCC.

RHHBY : 42.1100 (-0.59%)
EXEL : 22.27 (-1.33%)
BMY : 60.64 (-0.21%)
BAYRY : 12.9000 (+0.23%)
Opdivo(R) (nivolumab) in Combination with CABOMETYX(R) (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial

--Efficacy benefits were observed across key patient subgroups, including all International Metastatic Renal Cell Carcinoma Database Consortium risk and PD-L1 subgroups

BMY : 60.64 (-0.21%)
EXEL : 22.27 (-1.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 23.17
1st Resistance Point 22.72
Last Price 22.27
1st Support Level 22.02
2nd Support Level 21.77

See More

52-Week High 27.80
Fibonacci 61.8% 22.40
Last Price 22.27
Fibonacci 50% 20.74
Fibonacci 38.2% 19.07
52-Week Low 13.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar